ArticleCancer research2018
Small-Molecule Activators of Protein Phosphatase 2A for the Treatment of Castration-Resistant Prostate Cancer.
Open access · bronzeAbstract read
In one paragraph
Article in Cancer research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers.
0numbers the graph read from it
0cells of the map it votes in
55citing papers in PubMed
8.1field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 82 citations in OpenAlex.
- Protein phosphatase 2A regulates senescence and immunogenicity in medulloblastoma models.The Journal of clinical investigation · 2026Article
- Small Molecule Activators of Protein Phosphatase 2A Exert Global Stabilizing Effects on the Scaffold PR65.JACS Au · 2026Article
- Hexaraphane as a potential therapeutic strategy for tauopathies.Redox biology · 2026Article
- The role of PPP2R1A variants in gynecologic malignancies: a paradigm shift in immuno-oncology.Journal of translational medicine · 2026Review
- The protein phosphatase 2A-B56α complex regulates N-Myc degradation in neuroblastoma.The Journal of biological chemistry · 2026Article
- Sphingosine simultaneously inhibits nuclear import and activates PP2A by binding importins and PPP2R1A.The EMBO journal · 2025Article
- Clinical data investigation identifies MARK3 as an oncogenic driver in castration-resistant prostate cancer.Biochemistry and biophysics reports · 2025Article
- PP2A Attenuates Thoracic Aneurysm and Dissection in Mouse Models of Marfan Syndrome.Hypertension (Dallas, Tex. : 1979) · 2025Article
- Article
- Immune inhibitory receptor agonist therapeutics.Frontiers in immunology · 2025Review
- KRAS-mediated upregulation of CIP2A promotes suppression of PP2A-B56α to initiate pancreatic cancer development.Oncogene · 2024Article
- Integrated stress response plasticity governs normal cell adaptation to chronic stress via the PP2A-TFE3-ATF4 pathway.Cell death and differentiation · 2024Article
- Novel PP2A-Activating Compounds in Neuroblastoma.Cancers · 2024Article
- KRAS-mediated upregulation of CIP2A promotes suppression of PP2A-B56α to initiate pancreatic cancer development.bioRxiv : the preprint server for biology · 2024Article
- Integrated stress response plasticity governs normal cell adaptation to chronic stress via the PP2A-TFE3-ATF4 pathway.Research square · 2024Article
- Emerging Roles of B56 Phosphorylation and Binding Motif in PP2A-B56 Holoenzyme Biological Function.International journal of molecular sciences · 2024Review
- Targeting SMAD-Dependent Signaling: Considerations in Epithelial and Mesenchymal Solid Tumors.Pharmaceuticals (Basel, Switzerland) · 2024Review
- PP2A inhibition causes synthetic lethality in BRCA2-mutated prostate cancer models via spindle assembly checkpoint reactivation.The Journal of clinical investigation · 2024Article
- PP2A-based triple-strike therapy overcomes mitochondrial apoptosis resistance in brain cancer cells.Molecular oncology · 2023Article
- PP2A modulation overcomes multidrug resistance in chronic lymphocytic leukemia via mPTP-dependent apoptosis.The Journal of clinical investigation · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
30 authors at 6 institutions in 1 country.
Kimberly McClinch *Department of Medicine, Division of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York.
Rita A Avelar *Department of Medicine, Institute for Transformative Molecular Medicine, Case Western Reserve University, Cleveland, Ohio.
David Callejas *Department of Medicine, Institute for Transformative Molecular Medicine, Case Western Reserve University, Cleveland, Ohio.
Sudeh Izadmehr *Department of Medicine, Division of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York.
Danica WiredjaDepartment of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York.
Abbey PerlDepartment of Medicine, Institute for Transformative Molecular Medicine, Case Western Reserve University, Cleveland, Ohio.
Jaya SangodkarDepartment of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York.
David B KastrinskyCenter for Proteomics and Bioinformatics, Case Western Reserve University, Cleveland, Ohio.
Daniela SchlatzerDepartment of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York.
Maxwell CooperDepartment of Medicine, Institute for Transformative Molecular Medicine, Case Western Reserve University, Cleveland, Ohio.
Janna KiselarDepartment of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York.
Agnes StachnikDepartment of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York.
Shen YaoDepartment of Medicine, Division of Endocrine, Diabetes and Bone Diseases, Icahn School of Medicine at Mount Sinai, New York, New York.
Divya HoonDepartment of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York.
Daniel McQuaidDepartment of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York.
Nilesh ZawareCenter for Proteomics and Bioinformatics, Case Western Reserve University, Cleveland, Ohio.
Yixuan GongDepartment of Medicine, Division of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York.
David L BrautiganCenter for Cell Signaling, University of Virginia School of Medicine, Charlottesville, Virginia.
Stephen R PlymateDepartment of Medicine, University of Washington School of Medicine, Seattle, Washington.
Cynthia C T SprengerDepartment of Medicine, University of Washington School of Medicine, Seattle, Washington.
William K OhDepartment of Medicine, Division of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York.
Alice C LevineDepartment of Medicine, Division of Endocrine, Diabetes and Bone Diseases, Icahn School of Medicine at Mount Sinai, New York, New York.
Alexander KirschenbaumDepartment of Urology, Icahn School of Medicine at Mount Sinai, New York, New York.
John P SfakianosDepartment of Urology, Icahn School of Medicine at Mount Sinai, New York, New York.
Rosalie SearsDepartment of Molecular and Medical Genetics, Oregon Health and Science University, Portland, Oregon.
Analisa DiFeoCase Comprehensive Cancer Center, Case Western Reserve University, Cleveland, Ohio.
Yiannis IoannouDepartment of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York.
Michael OhlmeyerCenter for Proteomics and Bioinformatics, Case Western Reserve University, Cleveland, Ohio.
Goutham NarlaDepartment of Medicine, Institute for Transformative Molecular Medicine, Case Western Reserve University, Cleveland, Ohio. matthew.galsky@mssm.edu goutham.narla@case.edu.
Matthew D GalskyDepartment of Medicine, Division of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York. matthew.galsky@mssm.edu goutham.narla@case.edu.
Icahn School of Medicine at Mount Sinai · USCase Western Reserve University · USTisch Hospital · USUniversity of Washington · USOregon Health & Science University · USUniversity of Virginia · US
Funding
MEDICAL SCIENTIST TRAINING PROGRAMT32GM007250 · NIGMS · CASE WESTERN RESERVE UNIVERSITY · PI HUANG, ALEX YEE-CHEN · 1985 to 2023
$33.4MHydroxylation regulation of c-MycR01CA186241 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI Mu-Shui Dai, ROSALIE C SEARS · 2015 to 2026
$4.2MNRSA Training CoreTL1TR002549 · NCATS · CASE WESTERN RESERVE UNIVERSITY · PI HARDING, CLIFFORD V · 2018 to 2022
$2.9MThe Role of post-translational activation of Myc in pancreatic cancerR01CA196228 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI SEARS, ROSALIE C · 2015 to 2019
$2.0MSmall Molecule Activators of PP2A (SMAPs) for Prostate Cancer TherapyR01CA181654 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI NARLA, GOUTHAM · 2015 to 2019
$1.9MNCATS NIH HHS TL1 TR002549NCI NIH HHS R01 CA181654NCI NIH HHS R01 CA186241NCI NIH HHS R01 CA196228NIGMS NIH HHS T32 GM007250
Abstract
Primary prostate cancer is generally treatable by androgen deprivation therapy, however, later recurrences of castrate-resistant prostate cancer (CRPC) that are more difficult to treat nearly always occur due to aberrant reactivation of the androgen receptor (AR). In this study, we report that CRPC cells are particularly sensitive to the growth-inhibitory effects of reengineered tricyclic sulfonamides, a class of molecules that activate the protein phosphatase PP2A, which inhibits multiple oncogenic signaling pathways. Treatment of CRPC cells with small-molecule activators of PP2A (SMAP)
Indexed as
AnimalsCell Line, TumorEnzyme ActivatorsHeterograftsHumansMaleMiceMice, SCIDPhosphoproteinsProstatic Neoplasms, Castration-ResistantProtein Phosphatase 2CProteomicsReceptors, AndrogenRNA, MessengerSmall Molecule LibrariesEnzyme ActivatorsPhosphoproteinsPPM1A protein, humanProtein Phosphatase 2CReceptors, AndrogenRNA, MessengerSmall Molecule Libraries
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.